Halberd Corporation (HALB)
USD 0.0
(-8.33%)
USD 0.0
(-8.33%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 | 144.72 Thousand USD | 1.14% |
| 2023 | 143.08 Thousand USD | 1.87% |
| 2022 | 140.46 Thousand USD | 28.07% |
| 2021 | 109.67 Thousand USD | 5357.86% |
| 2020 | -2086.00 USD | 0.0% |
| 2019 | - USD | 0.0% |
| 2017 | 460.44 Thousand USD | -32.64% |
| 2016 | 683.58 Thousand USD | 0.0% |
| 2008 | 309.51 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 141.13 Thousand USD | -1.36% |
| 2024 Q4 | 144.72 Thousand USD | 0.37% |
| 2024 Q3 | 144.19 Thousand USD | 0.6% |
| 2024 Q2 | 143.33 Thousand USD | 1.56% |
| 2023 Q4 | 143.08 Thousand USD | 30.54% |
| 2023 Q2 | 142.33 Thousand USD | -1.83% |
| 2023 Q1 | 144.99 Thousand USD | 3.23% |
| 2023 FY | 143.08 Thousand USD | 1.87% |
| 2023 Q3 | 109.6 Thousand USD | -22.99% |
| 2022 Q4 | 140.46 Thousand USD | -0.97% |
| 2022 Q3 | 141.83 Thousand USD | 18.14% |
| 2022 Q2 | 120.05 Thousand USD | 12.9% |
| 2022 Q1 | 106.34 Thousand USD | -3.04% |
| 2022 FY | 140.46 Thousand USD | 28.07% |
| 2021 Q4 | 109.67 Thousand USD | 278.24% |
| 2021 FY | 109.67 Thousand USD | 5357.86% |
| 2021 Q1 | 2086.00 USD | 0.0% |
| 2021 Q3 | 28.99 Thousand USD | 0.0% |
| 2020 FY | -2086.00 USD | 0.0% |
| 2019 FY | - USD | 0.0% |
| 2017 FY | 460.44 Thousand USD | -32.64% |
| 2016 FY | 683.58 Thousand USD | 0.0% |
| 2009 Q2 | 24.95 Thousand USD | -92.33% |
| 2009 Q3 | 77.17 Thousand USD | 209.27% |
| 2009 Q1 | 325.18 Thousand USD | 5.06% |
| 2008 FY | 309.51 Thousand USD | 0.0% |
| 2008 Q4 | 309.51 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1310.00 USD | 11147.405% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 97.438% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 99.662% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | 157.977% |
| Rebus Holdings, Inc. | 305 Thousand USD | 52.55% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | 102.296% |
| Qrons Inc. | 351.42 Thousand USD | 58.819% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 76.747% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 99.667% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | 809.139% |
| Skye Bioscience, Inc. | -5.72 Million USD | 102.529% |
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 99.082% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 96.486% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 63.986% |
| SQZ Biotechnologies Company | -36.23 Million USD | 100.399% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 93.546% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 84.391% |
| Mesoblast Limited | 55.85 Million USD | 99.741% |
| Marizyme, Inc. | 18.56 Million USD | 99.221% |
| Genus plc | 190.6 Million USD | 99.924% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 93.527% |
| Pharming Group N.V. | 109.8 Million USD | 99.868% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 83.177% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 88.078% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 78.718% |
| ContraFect Corporation | -6.02 Million USD | 102.402% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | -7.488% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 87.475% |
| IMV Inc. | 7.67 Million USD | 98.113% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 97.37% |
| MultiCell Technologies, Inc. | 90.04 USD | -160629.676% |
| ONE Bio Corp. | 9.04 Million USD | 98.399% |
| Accustem Sciences Inc. | -733.97 Thousand USD | 119.717% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 98.882% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.36 Million USD | 89.421% |
| Q BioMed Inc. | 4.06 Million USD | 96.435% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 99.526% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 85.639% |
| Biomind Labs Inc. | 711.4 Thousand USD | 79.657% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 99.761% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 92.762% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 98.87% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 59.767% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | -3.517% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | -628.449% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 93.428% |
| GB Sciences, Inc. | 1.74 Million USD | 91.718% |
| Alpha Cognition Inc. | -183.78 Thousand USD | 178.743% |
| HST Global, Inc. | 96.79 Thousand USD | -49.516% |
| CSL Limited | 10.52 Billion USD | 99.999% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 29.821% |
| Enzolytics Inc. | 981.65 Thousand USD | 85.257% |
| Agentix Corp. | 37.63 Thousand USD | -284.579% |
| Resverlogix Corp. | 6.45 Million USD | 97.757% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | 121.501% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | -2.02 Billion USD | 100.007% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 100.308% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 97.953% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 94.657% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | 101.637% |
| AVAX Technologies, Inc. | -5.9 Million USD | 102.452% |
| Zenith Capital Corp. | 10.06 Thousand USD | -1338.007% |
| Genscript Biotech Corporation | -1.06 Billion USD | 100.014% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 27.795% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 93.935% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 12.029% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | 890.048% |
| Kadimastem Ltd | -253.1 Thousand USD | 157.179% |
| Helix BioMedix, Inc. | -2.57 Million USD | 105.631% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 99.286% |
| BioStem Technologies, Inc. | 4.47 Million USD | 96.764% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 28.09% |
| LadRx Corporation | -2.03 Million USD | 107.106% |
| Cell Source, Inc. | 9.23 Million USD | 98.432% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 77.215% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 77.215% |
| NovAccess Global Inc. | 2.17 Million USD | 93.357% |
| Affymax, Inc. | -5.59 Million USD | 102.586% |
| Itoco Inc. | 228.3 Thousand USD | 36.611% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | -6.421% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 97.08% |
| Mobile Lads Corp. | 484.23 Thousand USD | 70.113% |
| CytoDyn Inc. | 20.26 Million USD | 99.286% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | 22468.006% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | 1661.455% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 98.122% |
| SYBLEU INC | 473.71 Thousand USD | 69.45% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 96.753% |
| International Stem Cell Corporation | 2.59 Million USD | 94.412% |
| Bioxytran, Inc. | 1.89 Million USD | 92.379% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -131.876% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 93.364% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 95.786% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 98.308% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 81.268% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | 111.578% |
| Neutra Corp. | 52.18 Thousand USD | -177.312% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | 105.814% |
| PureTech Health plc | -167.19 Million USD | 100.087% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | 159.092% |
| IXICO plc | -4.44 Million USD | 103.256% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 98.905% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 99.736% |
| CSL Limited | 10.52 Billion USD | 99.999% |
| Cellectis S.A. | -43.81 Million USD | 100.33% |